Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Disease or Syndrome > Inflammatory Bowel Diseases

Inflammatory Bowel Diseases

Inflammatory Bowel Diseases refer to a group of chronic, relapsing conditions affecting the gastrointestinal tract.
This umbrella term encompasses disorders such as Crohn's Disease and Ulcerative Colitis, which are characterized by inflammation, ulceration, and impaired intestinal function.
Symptoms may include abdominal pain, diarrhea, rectal bleeding, and weight loss.
The exact causes are not fully understood, but are thought to involve a complex interplay of genetic, immunologic, and environmental factors.
Effective management often requires a multidisciplinary approach, including medication, dietary modifications, and in some cases, surgical intervention.
Ongoing research aims to better understand the pathophysiology and develop more targeted, individualized therapies to improve quality of life for those affected by these debilitating conditions.

Most cited protocols related to «Inflammatory Bowel Diseases»

1
Rosiglitazone for Ulcerative Colitis: A Placebo-Controlled Trial
Data for this study were acquired from a recently completed placebo-controlled randomized trial of rosiglitazone for mild to moderately active ulcerative colitis (clinicaltrials.gov #NCT00065065) which has been described in greater detail previously.7 (link) The trial used a slight modification of the Mayo score to assess disease activity (Table 1). Specifically, the bleeding component as described in the Mayo index was modified such that a score of 3 required both visible blood in 50% or more of bowel movements and at least some bowel movements with blood alone.
The study included 105 patients with mild to moderately active disease defined as a total DAI score of 4 to 10, inclusively. Patients were randomized in a 1:1 ratio to receive either rosiglitazone 4 mg or placebo twice daily for 12 weeks. Disease activity was measured at randomization and every four weeks thereafter until week 12, however lower endoscopy was only completed at week 0 and week 12, such that only a partial Mayo score (9 point scale that excludes the endoscopic appearance of the mucosa) could be calculated at the interim visits. In the very early accrual period of the study, a follow-up visit was included at week 2. Without knowledge of the response rates in either arm, the Data and Safety Monitoring Board (DSMB) requested that the week 2 follow-up evaluation be eliminated with the hopes of minimizing the placebo response rate and maximizing recruitment and retention.6 (link), 8 (link), 9 (link) Eighteen patients completed the week 2 follow-up visit.
During the course of the study, patients could be treated with other conventional medications used to treat active ulcerative colitis including mesalamine, oral corticosteroids, immunomodulators, or topical therapies (mesalamine or corticosteroids) at stable doses. Use of corticosteroids at doses greater than 20mg per day of prednisone or the equivalent was an exclusion criterion. Steroid tapering was not permitted during the study.
In anticipation of this sub-study, at each visit we also included questions about change in disease activity compared to the previous visit and compared to the randomization visit on a global seven-point scale (Table 2). The choices included much better, moderately better, a little better, unchanged, a little worse, moderately worse, and much worse. Patients also graded their current disease activity at each visit on a 6 point Likert scale – perfect, very good (minimal symptoms), good (only mild symptoms), moderately active, moderately severe, or severe. Data on quality of life were measured with the Inflammatory Bowel Disease Questionnaire (IBDQ) authored by Dr. Jan Irvine under license from McMaster University, Hamilton, Canada.10 (link)
Lewis J.D., Chuai S., Nessel L., Lichtenstein G.R., Aberra F.N, & Ellenberg J.H. (2008). Use of the Non-invasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis. Inflammatory bowel diseases, 14(12), 1660-1666.
Publication 2008
Adrenal Cortex Hormones BLOOD Clinical Trials Data Monitoring Committees Defecation Endoscopy Endoscopy, Gastrointestinal Immunologic Adjuvants Inflammatory Bowel Diseases Mesalamine Mucous Membrane Patients Pharmaceutical Preparations Placebos Prednisone Retention (Psychology) Rosiglitazone Steroids Ulcerative Colitis
2
Expanding PheWAS Phenotype Categorization
In this study, we revised and expanded our earlier PheWAS phenotype categorization to a total of 1,645 phenotypes identified from International Classification of Disease, Ninth revision, Clinical Modification (ICD9) codes. (Our initial PheWAS phenotype categorization included 744 phenotypes9 (link).) The ICD9 coding system is divided into four components: diseases, signs and symptoms (“three digit” codes, 001–999), external causes of injury (“E” codes), procedures (“two digit” codes 00.0–99.9) and supplemental classifications (“V” codes). The prior PheWAS code groupings included only diseases, signs and symptoms (three digit) ICD9 codes9 (link). We revised and expanded the PheWAS phenotypes by (i) adding V codes (commonly used to record personal histories of given diseases) and E codes (which refer to external causes of injury) to the PheWAS code mapping, (ii) redesigning the code system to be hierarchical, such that one phenotype could be a parent of another subphenotype (e.g., cardiac arrhythmias is a parent of atrial fibrillation, atrial flutter and other arrhythmias), and (iii) including more granular phenotypes into the coding system (e.g., “type 1 diabetes with ketoacidosis”). Creation of hierarchical phenotypes included creation of phenotypes not present in the ICD9 billing hierarchy, such as “inflammatory bowel disease” as the parent phenotype for “Crohn’s disease” and “ulcerative colitis.” In this process, we were guided by the hierarchical organization of the Clinical Classifications Software (CCS) produced by the Agency for Healthcare Research and Quality42 (link); the 2011 version of the CCS contains 727 phenotypes. The resulting PheWAS code group currently contains 1,645 phenotypes, 1,358 of which had at least 25 cases (a prevalence of 0.18% in our data set) in the eMERGE cohort, our threshold for these analyses. The current version of the PheWAS codes, with ICD9 mappings and control groups, is available from http://knowledgemap.mc.vanderbilt.edu/research/content/phewas.
Denny J.C., Bastarache L., Ritchie M.D., Carroll R.J., Zink R., Mosley J.D., Field J.R., Pulley J.M., Ramirez A.H., Bowton E., Basford M.A., Carrell D.S., Peissig P.L., Kho A.N., Pacheco J.A., Rasmussen L.V., Crosslin D.R., Crane P.K., Pathak J., Bielinski S.J., Pendergrass S.A., Xu H., Hindorff L.A., Li R., Manolio T.A., Chute C.G., Chisholm R.L., Larson E.B., Jarvik G.P., Brilliant M.H., McCarty C.A., Kullo I.J., Haines J.L., Crawford D.C., Masys D.R, & Roden D.M. (2013). Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nature biotechnology, 31(12), 1102-1110.
Publication 2013
Atrial Fibrillation Atrial Flutter Cardiac Arrhythmia Crohn Disease Diabetic Ketoacidosis Fingers Inflammatory Bowel Diseases Injuries Parent Phenotype Ulcerative Colitis
3
Comprehensive Analysis of Inflammatory Bowel Disease
The Clinical IBD data was obtained from the Inflammatory Bowel Disease Multiomics Database [15 (link)]. A large cohort of IBD patients were included for this study. The stool samples of CD (n = 266), UC (n = 144), and non-IBD (n = 135) were collected. The extraction and purification steps have already been described previously [29 (link)]. The quality control (QC, n = 59) samples were also included. All clinical information from the samples is summarized in Table S2. The data format conversion and initial parameters were identical to the NIST dilution series above. The TICs of the data are shown in Figure S4. Parameter optimization was performed using four QC samples from each group randomly selected from the whole batch. The optimized parameters are provided in Table S1. The data analysis was finished with the whole MetaboAnalystR 3.0 workflow. Functional analysis was performed by integration with Mummichog2 for the comparisons between different groups (cutoff of p value 2.0 × 10−6).
Pang Z., Chong J., Li S, & Xia J. (2020). MetaboAnalystR 3.0: Toward an Optimized Workflow for Global Metabolomics. Metabolites, 10(5), 186.
Full text: Click here
Publication 2020
Feces Inflammatory Bowel Diseases Patients Technique, Dilution Tic Disorder
4
Evaluating Endoscopic Severity in Ulcerative Colitis
Ten specialists in inflammatory bowel disease (IBD, the authors) graded videos of flexible sigmoidoscopy according to their own practice, in the absence of clinical information. Twenty-four representative videos were selected to represent the widest range of UC activity, guided by the Mayo Clinic score (by PK and BRY) from a library of 670 videos recorded in a standard manner during clinical trials for the treatment of moderately active UC6 (link) (EUDRACT 2006-001310-32). Within each Mayo Clinic score stratum, consecutive videos were reviewed by one of the co-authors for image quality. Satisfactory quality recordings (sharp image, sufficient bowel preparation) were selected. Videos from fibreoptic endoscopes were discarded. Sixteen videos represented the complete range of severity; 24 videos enabled choice from additional videos in the mid-range of severity, most likely to be affected by interobserver variation. Each investigator was randomly assigned 16 of the 24 videos in randomised order using a set of Latin squares: a core set of eight videos that all investigators evaluated (two for each Baron score) and eight of 16 non-core videos, This kept the number of evaluations by each investigator in the 2–3 h session to a manageable number (16), while still having a common core set (8) and a broad overall pool of videos (24). Investigators were explicitly advised not to apply the Baron index themselves, to avoid biasing their overall assessment of severity in relation to this index. To assess potential scoring differences based on the length of the video,11 (link) each investigator had two pairs that were shortened from 10–15 min to approximately 5 min, giving a total of 18 videos for each investigator to view. Descriptors of endoscopic severity were selected from previous studies.3 (link)
8 (link)
9 (link)
12 (link)
13 (link) Investigators recorded the presence or absence of 11 descriptors. Overall severity was assessed on a visual analogue scale (VAS, between 0=completely normal and 100=worst ever seen).
To substantiate variability in endoscopic assessment, the level of the Baron index derived from the assessments by investigators was compared with the level assigned by the central reader in the original trial.7 The precise wording of definitions and video clips illustrating anchor points on three-, four- or five-point Likert scales of severity for each descriptor, were subsequently agreed by consensus during a video teleconference between investigators (table 1).
Travis S.P., Schnell D., Krzeski P., Abreu M.T., Altman D.G., Colombel J.F., Feagan B.G., Hanauer S.B., Lémann M., Lichtenstein G.R., Marteau P.R., Reinisch W., Sands B.E., Yacyshyn B.R., Bernhardt C.A., Mary J.Y, & Sandborn W.J. (2011). Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut, 61(4), 535-542.
Publication 2011
BAD protein, human cDNA Library Clip Endoscopes Endoscopy Inflammatory Bowel Diseases Intestines Proctosigmoidoscopy Specialists Vision Visual Analog Pain Scale
5
Microbiome Analysis of Inflammatory Bowel Diseases
We also include a brief analysis of microbiome data from a study of inflammatory bowel diseases (IBDs) [28] (link). This comprised faecal samples from 78 individuals where the V5-6 region of the 16S rRNA gene was pyrosequenced using 454. 35 samples were from healthy individuals, 12 from individuals with colonic Crohn's disease (CCD), 15 from individuals exhibiting ileal Crohn's disease (ICD), and 16 from individuals with ulcerative colitis (UC). We processed the data as above. This gave a total of 134,276 reads with individual samples varying in size from 394 to 3,258 with a median of 1,710 reads. 93 separate genera were observed in these samples with a genera diversity per sample that varied from 8 to 33 with a median of 22.
Holmes I., Harris K, & Quince C. (2012). Dirichlet Multinomial Mixtures: Generative Models for Microbial Metagenomics. PLoS ONE, 7(2), e30126.
Full text: Click here
Publication 2012
Crohn Disease Feces Granulomatous Colitis Ileal Diseases Ileum Inflammatory Bowel Diseases Microbiome Ribosomal RNA Genes Ulcerative Colitis

Most recents protocols related to «Inflammatory Bowel Diseases»

1
Long-term Conditions in Welsh Residents
Residents of Wales diagnosed for the first time with at least one of 17 long-term conditions between January 2000 and December 2021 were identified using ICD-10 or Read v2 codes (Supplementary Tables S2 and S3). The conditions included were anxiety disorders, asthma, atrial fibrillation, coronary heart disease (CHD), chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), dementia, depression, diabetes mellitus, epilepsy, heart failure, hypertension, inflammatory bowel disease (IBD), osteoporosis, peripheral vascular disease (PVD), rheumatoid arthritis, and stroke and transient ischaemic attack (TIA). These conditions comprise most of the general practice ‘Quality and Outcomes (QOF) Framework’.13 In addition, individuals diagnosed with three diabetes subtypes (type 1, type 2, undetermined) were identified using an algorithm.14 (link) ‘Undetermined type diabetes’ was assigned when criteria for type 1 or type 2 were not met.
The final study dataset excluded records missing week of birth or sex, or where the diagnosis date was before birth or after death dates.
Qi C., Osborne T., Bailey R., Cooper A., Hollinghurst J.P., Akbari A., Crowder R., Peters H., Law R.J., Lewis R., Smith D., Edwards A, & Lyons R.A. (2023). Impact of COVID-19 pandemic on incidence of long-term conditions in Wales: a population data linkage study using primary and secondary care health records. The British Journal of General Practice, 73(730), e332-e339.
Full text: Click here
Publication 2023
Anxiety Disorders Asthma Atrial Fibrillation Cerebrovascular Accident Childbirth Chronic Kidney Diseases Chronic Obstructive Airway Disease Congestive Heart Failure Dementia Diabetes Mellitus Diagnosis Epilepsy Heart Disease, Coronary High Blood Pressures Inflammatory Bowel Diseases Osteoporosis Peripheral Vascular Diseases Rheumatoid Arthritis Training Programs Transient Ischemic Attack
2
Comparison of Anesthesia Techniques for Lung Nodule VATS
This study was approved by the Ethics Committee of Nanjing Drum Tower Hospital (No. 2018-160-02) and registered in the Chinese Clinical Trial Registry (ChiCTR2100054057, https://www.chictr.org.cn, June 5, 2022; Yan Wang, M D.). Clinical trial procedures followed the principles of the Declaration of Helsinki.
A total of 132 patients with lung nodules receiving VATS with general anesthesia (the GA Group), ultrasound-guided RIB (RIB Group), or PVB (the PVB Group) in the plane of the T5 level using 0.4% ropivacaine (Zhejiang Xianju Pharmaceutical Co., Ltd., Zhejiang, China) at 3 mg/kg between June 8th, 2022, and August 10th, 2022, were recruited.
Inclusion criteria are as follows: (1) 18–80 years of age; (2) American Society of Anesthesiologists (ASA) Class I-III; and (3) written informed consent was obtained.
Exclusion criteria are as follows: (1) Allergy to local anesthetics, nonsteroidal anti-inflammatory drugs, and opioids; (2) infection of the skin at the puncture site; (3) peptic ulcer disease or inflammatory bowel disease; (4) renal deficiency; (5) transferring to thoracotomy; (6) daily use of opioids; and (7) bilateral operation.
Wang Y., Gu X., Huang S., Shi M., He X, & Ma Z. (2023). Ultrasound-Guided Rhomboid Block versus Paravertebral Block in Postoperative Analgesia for Video-Assisted Thoracoscopic Surgery: A Prospective Randomized Controlled Clinical Trial. Pain Research & Management, 2023, 3924511.
Full text: Click here
Publication 2023
Anesthesiologist Anti-Inflammatory Agents, Non-Steroidal Chinese Ethics Committees, Clinical General Anesthesia Hypersensitivity Inflammatory Bowel Diseases Kidney Local Anesthetics Opioids Patients Peptic Ulcer Pharmaceutical Preparations Punctures Ropivacaine Skin Diseases, Infectious Thoracic Surgery, Video-Assisted Thoracotomy Ultrasonics
3
Colorectal Polyp Risk Assessment
Clinical outcomes were collected for all patients who provided a viable sample, by requesting copies of examination reports from participating sites every month. All diagnoses were determined by reviewing endoscopy, radiology, and histology reports, clinic letters, and urgent referral forms provided by the participating sites. Patient and clinical data included symptoms, reasons for the referral, medical history, and sociodemographic factors. All diagnoses were verified by medical members of the central research team.
All neoplastic bowel polyps, either adenomatous polyps or sessile serrated polyps, were identified and were given a risk of either ‘low’, ‘intermediate’, or ‘high’ depending on their size and frequency; contemporary UK and European guidelines were used in this study23 ,24 (link), with low risk defined as 1–2 adenomas less than 10 mm, intermediate risk as 3–4 small adenomas less than 10 mm or one adenoma 10 mm or more, and high risk as five or more adenomas less than 10 mm or three or more adenomas with at least one 10 mm or more.
Non-neoplastic polyps, such as hyperplastic, inflammatory, or pseudopolyps, were classified separately. Patients with a risk score for their polyps at first, second, or third examinations had their cumulative number and/or highest risk polyp taken as their final score. Remaining bowel pathology was classified as one of CRC, inflammatory bowel disease (colitis/proctitis), diverticulosis, haemorrhoids, normal examination, or procedure stopped/incomplete. Patients with concurrent polyps and CRC were classified as CRC and not included in the analysis, as our target group for this study was those without CRC in whom we could potentially identify polyps and plan for removal before they could progress to CRC.
Bath M.F., Malhi A., Ayling R.M., Seward E., Pritchard-Jones K., Laszlo H.E., Hackshaw A, & Machesney M.R. (2023). Faecal immunochemical testing for haemoglobin in detecting bowel polyps in symptomatic patients: multicentre prospective cohort study. BJS Open, 7(2), zrac161.
Full text: Click here
Publication 2023
Adenoma Adenomatous Polyps Colitis Diagnosis Diverticulosis Endoscopy, Gastrointestinal Europeans Hemorrhoids Hyperplasia Inflammation Inflammatory Bowel Diseases Intestinal Polyps Intestines Neoplasms Patients Physical Examination Polyps Proctitis X-Rays, Diagnostic
4
Gut Microbiome in Aortic Dissection
A case–control study was performed at Fujian Heart Medical Center from January 2022 to May 2022. A total of 20 AAD patients (AAD group) were recruited in this study. Twenty healthy controls (control group) matched for gender, age, body mass index (BMI), and geographical region were recruited at the physical examination center during the same period. The inclusion criteria were as follows: (1) age ≥ 18 years; (2) AAD confirmed by computed tomography angiography, magnetic resonance angiography, or ultrasound. The exclusion criteria were as follows: (1) usage of antibiotics, glucocorticoids, immunosuppressants, or probiotics within 3 months before stool sampling; (2) suffering from digestive system tumors, digestive tract infections, inflammatory bowel disease, or other diseases; (3) history of intestinal surgery; (4) history of recurrent diarrhea or constipation within 1 month.
Jiang F., Cai M., Peng Y., Li S., Liang B., Ni H, & Lin Y. (2023). Changes in the gut microbiome of patients with type a aortic dissection. Frontiers in Microbiology, 14, 1092360.
Full text: Click here
Publication 2023
Antibiotics Computed Tomography Angiography Constipation Diarrhea Digestive System Neoplasms Feces Gastrointestinal Tract Glucocorticoids Heart Immunosuppressive Agents Index, Body Mass Infection Inflammatory Bowel Diseases Intestines Magnetic Resonance Angiography Operative Surgical Procedures Patients Physical Examination Probiotics Ultrasonography
5
Validated Autoimmune Disease Diagnoses
The outcome of interest in this study was newly diagnosed autoimmune diseases after the index dates. In Taiwan, people with several autoimmune diseases can apply for catastrophic illness certification to receive a copayment exemption from the NHI program, and all the applications are reviewed by rheumatologists. These autoimmune diseases, including SLE, systemic sclerosis, Sjögren’s syndrome, inflammatory myopathy, rheumatoid arthritis, Behcet’s syndrome, systemic vasculitis, type I diabetes mellitus, multiple sclerosis, myasthenia gravis, inflammatory bowel diseases, autoimmune hemolytic anemia, and pemphigus, were identified from the Registry for Catastrophic Illness, and thus the diagnoses should be valid. For autoimmune diseases that did not fulfill the requirements to be considered catastrophic illnesses in Taiwan, including ankylosing spondylitis, post-infectious arthritis, uveitis, psoriasis, autoimmune thyroid disease, primary adrenocortical insufficiency, Guillain–Barré syndrome, autoimmune encephalomyelitis, and celiac disease, one hospital admission or at least three outpatient visits with relevant ICD-9-CM or ICD-10-CM codes were regarded as the confirmed diagnosis (S1 Table). The follow-up of study participants started on the index dates and continued until the confirmation of study outcomes, death, or August 31, 2018, whichever occurred first.
Shih H.I., Chi C.Y., Tsai P.F., Wang Y.P, & Chien Y.W. (2023). Re-examination of the risk of autoimmune diseases after dengue virus infection: A population-based cohort study. PLOS Neglected Tropical Diseases, 17(3), e0011127.
Full text: Click here
Publication 2023
Addison Disease Anemia, Autoimmune Hemolytic Ankylosing Spondylitis Arthritis, Reactive Autoimmune Diseases Behcet Syndrome Catastrophic Illness Celiac Disease Diabetes Mellitus, Insulin-Dependent Diagnosis Experimental Autoimmune Encephalomyelitis Guillain-Barre Syndrome Inflammatory Bowel Diseases Multiple Sclerosis Myasthenia Gravis Myositis Outpatients Pemphigus Psoriasis Rheumatoid Arthritis Rheumatologist Sjogren's Syndrome Systemic Scleroderma Thyroid Diseases Thyroid Gland Uveitis

Top products related to «Inflammatory Bowel Diseases»

1
Dextran sulfate sodium (dss) by MP Biomedicals
Sourced in United States, France, Germany, China, Canada, United Kingdom, Australia, Japan, Panama, Philippines
The DSS is a laboratory instrument designed for the separation and analysis of molecules and particles in complex samples. It utilizes a specialized technique called differential sedimentation to achieve precise separation and characterization of the components within a sample. The core function of the DSS is to provide accurate and reliable data on the size, distribution, and concentration of the analytes present, without interpretation or extrapolation on its intended use.
2
Psycinfo by EBSCO
PsycINFO is a comprehensive database that provides access to the scholarly literature in the field of psychology and related behavioral and social sciences. It includes citations and abstracts from academic journals, books, book chapters, and dissertations.
3
Stool preservative tube by Norgen Biotek
Sourced in Canada
The Stool Preservative Tube is a laboratory equipment designed to collect and preserve stool samples for analysis. It is a self-contained system that ensures the integrity of the sample during transport and storage.
4
Cba j by Jackson ImmunoResearch
Sourced in United States, Montenegro
The CBA/J is a laboratory mouse strain that can be used for various research applications. It serves as a model for immunological studies and other biomedical investigations.
5
C57bl 6j by Jackson ImmunoResearch
Sourced in United States, Montenegro, Germany, United Kingdom, Japan, China, Canada, Australia, France, Colombia, Netherlands, Spain
C57BL/6J is a mouse strain commonly used in biomedical research. It is a common inbred mouse strain that has been extensively characterized.
6
Dithiothreitol (dtt) by Merck Group
Sourced in United States, Germany, United Kingdom, Italy, Sao Tome and Principe, France, China, Switzerland, Macao, Spain, Australia, Canada, Belgium, Sweden, Brazil, Austria, Israel, Japan, New Zealand, Poland, Bulgaria
Dithiothreitol (DTT) is a reducing agent commonly used in biochemical and molecular biology applications. It is a small, water-soluble compound that helps maintain reducing conditions and prevent oxidation of sulfhydryl groups in proteins and other biomolecules.
7
Sas v9 by SAS Institute
Sourced in United States, Austria, United Kingdom, Cameroon, Belgium, Israel, Japan, Australia, France, Germany
SAS v9.4 is a software product developed by SAS Institute. It is a comprehensive data analysis and statistical software suite. The core function of SAS v9.4 is to provide users with tools for data management, analysis, and reporting.
8
Oc sensor by Eiken Chemical
Sourced in Japan
The OC-Sensor is a laboratory equipment designed to measure and analyze certain chemical compounds. It is a compact and automated device capable of precise quantitative analysis. The core function of the OC-Sensor is to detect and measure the levels of specific chemical substances in a sample, providing accurate data for various analytical applications.
9
Cinahl by EBSCO
Sourced in United States
CINAHL is a comprehensive research database that provides access to a wide range of information related to nursing, allied health, and other healthcare-related fields. It indexes journal articles, books, and other materials from more than 5,000 sources, covering topics such as nursing, biomedicine, health sciences librarianship, consumer health, and more.

More about "Inflammatory Bowel Diseases"

Inflammatory Bowel Diseases (IBD) encompass a group of chronic, relapsing conditions affecting the gastrointestinal tract, including Crohn's Disease (CD) and Ulcerative Colitis (UC).
These debilitating disorders are characterized by inflammation, ulceration, and impaired intestinal function, leading to symptoms such as abdominal pain, diarrhea, rectal bleeding, and weight loss.
The exact causes of IBD are not fully understood, but are thought to involve a complex interplay of genetic, immunologic, and environmental factors.
Effective management often requires a multidisciplinary approach, including medication, dietary modifications, and in some cases, surgical intervention.
Ongoing research, utilizing animal models like DSS-induced colitis in CBA/J and C57BL/6J mice, as well as stool sample analysis with OC-Sensor and CINAHL databases, aims to better understand the pathophysiology of IBD.
This research is crucial for developing more targeted, individualized therapies to improve the quality of life for those affected by these debilitating conditions.
PubCompare.ai, an innovative AI-driven platform, is revolutionizing IBD research by streamlining the process of identifying the best protocols from literature, pre-prints, and patents.
By performing intelligent comparisons, the platform can help researchers locate the optimal solutions and accelerate breakthroughs in IBD treatment.
With its user-friendly interface and powerful analytical capabilities, PubCompare.ai is a valuable tool for scientists working to unravel the complexities of Inflammatory Bowel Diseases.